- Home
- TGTX vs VRRM Comparison
TGTX vs VRRM Comparison
Compare TGTX & VRRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGTX
- VRRM
- Stock Information
- Founded
- TGTX 1993
- VRRM 1987
- Country
- TGTX United States
- VRRM United States
- Employees
- TGTX N/A
- VRRM 1879
- Industry
- TGTX Biotechnology: Pharmaceutical Preparations
- VRRM Transportation Services
- Sector
- TGTX Health Care
- VRRM Consumer Discretionary
- Exchange
- TGTX Nasdaq
- VRRM Nasdaq
- Market Cap
- TGTX 4.2B
- VRRM 3.9B
- IPO Year
- TGTX 1995
- VRRM N/A
- Fundamental
- Price
- TGTX $32.87
- VRRM $24.34
- Analyst Decision
- TGTX Strong Buy
- VRRM Strong Buy
- Analyst Count
- TGTX 4
- VRRM 4
- Target Price
- TGTX $42.50
- VRRM $27.88
- AVG Volume (30 Days)
- TGTX 2.0M
- VRRM 722.9K
- Earning Date
- TGTX 11-03-2025
- VRRM 10-30-2025
- Dividend Yield
- TGTX N/A
- VRRM N/A
- EPS Growth
- TGTX N/A
- VRRM N/A
- EPS
- TGTX 0.36
- VRRM 0.24
- Revenue
- TGTX $454,069,000.00
- VRRM $906,330,000.00
- Revenue This Year
- TGTX $82.58
- VRRM $8.04
- Revenue Next Year
- TGTX $44.99
- VRRM $7.27
- P/E Ratio
- TGTX $88.20
- VRRM $102.87
- Revenue Growth
- TGTX 30.96
- VRRM 6.24
- 52 Week Low
- TGTX $21.16
- VRRM $19.51
- 52 Week High
- TGTX $46.48
- VRRM $28.25
- Technical
- Relative Strength Index (RSI)
- TGTX 61.27
- VRRM 46.75
- Support Level
- TGTX $31.29
- VRRM $23.85
- Resistance Level
- TGTX $32.56
- VRRM $25.10
- Average True Range (ATR)
- TGTX 1.15
- VRRM 0.53
- MACD
- TGTX 0.37
- VRRM -0.06
- Stochastic Oscillator
- TGTX 89.67
- VRRM 31.29
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
About VRRM Verra Mobility Corporation
Verra Mobility Corp is a provider of smart mobility technology solutions, principally operating throughout the United States, Australia, Europe and Canada. The company develops and uses technology and data intelligence to help make transportation safer and easier. It operates in three segments namely Commercial Services, Government Solutions, and Parking Solutions. It generates maximum revenue from the Commercial Services segment. The commercial Services segment delivers tolling and violation management services to rental car companies, commercial fleet vehicle owners, and violation issuing authorities.